Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To investigate the efficacy and safety of liraglutide added to capped insulin doses in subjects with type 1 diabetes. RESEARCH DESIGN AND METHODS: A 26-week, placebo-controlled, double-blind, parallel-group trial enrolling 835 subjects randomized 3:1 receiving once-daily subcutaneous liraglutide (1.8, 1.2, and 0.6 mg) or placebo added to an individually capped total daily dose of insulin. RESULTS: Mean baseline glycated hemoglobin (HbA1c) (8.1% [65.0 mmol/mol]) was significantly decreased with liraglutide versus placebo at week 26 (1.8 mg: –0.33% [3.6 mmol/mol]; 1.2 mg: –0.22% [2.4 mmol/mol]; 0.6 mg: –0.23% [2.5 mmol/mol]; placebo: 0.01% [0.1 mmol/mol]). Liraglutide significantly reduced mean body weight (–5.1, –4.0, and –2.5 kg for 1.8, 1.2, and 0.6 mg, respectively) versus placebo (–0.2 kg). Significant reductions in daily insulin dose and increases in quality of life were seen with liraglutide versus placebo. There were higher rates of symptomatic hypoglycemia (21.3 vs. 16.6 events/patient/year; P = 0.03) with liraglutide 1.2 mg vs. placebo and of hyperglycemia with ketosis >1.5 mmol/L with liraglutide 1.8 mg vs. placebo (0.5 vs. 0.1 events/patient/year; P = 0.01). CONCLUSIONS: In a broad population of subjects with long-standing type 1 diabetes, liraglutide added to capped insulin reduced HbA1c, body weight, and insulin requirements but with higher rates of hypoglycemia for liraglutide 1.2 mg and hyperglycemia with ketosis for liraglutide 1.8 mg.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is a potential risk of severe hypoglycemia if persons with DM do not appropriately reduce the prandial insulin dosage.1171–1174”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1171]
In the citing paper
“The amylin analog pramlintide, the only other medication approved for the treatment of T1D, is administered with prandial insulin.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1171]
In the citing paper
“A1C reductions are consistently modest, and mild weight loss is common.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1171]
In the citing paper
“Tachyphylaxis is often seen after several years of therapy.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1171]
In the citing paper
“Nausea is a common adverse effect.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1171]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Self-citationSeaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 4×
“At 26 weeks, significantly more subjects receiving liraglutide 1.8 mg compared with placebo achieved the ADA target of HbA1c,7.0% (,53.0mmol/mol) (18.8 vs. 10.0%, respectively, odds ratio [OR] 2.12 [95% CI 1.11; 4.06], P = 0.0231) (Fig.”
BackgroundInfluentialMiller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
Self-citationon behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Health-Related Quality of Life and Treatment Satisfaction in Dutch Patients With Type 2 Diabetes
Redekop, W. K., Koopmanschap, M. A., Stolk, R. P., Rutten, G. E. H. M., Wolffenbuttel, B. H. R., & Niessen, L. W. (2002) · Diabetes Care · doi:10.2337/diacare.25.3.458 · Cited by 565
van Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.162 · Cited by 537 · cited 1×
“Furthermore, liraglutide decreases food intake (9) and has weight loss benefits in type 2 diabetes (10–14).”
BackgroundBradley, C., & Lewis, K. S. (1990) · Diabetic Medicine · doi:10.1111/j.1464-5491.1990.tb01421.x · Cited by 379
Research works printed but not linked: 3
- FDA, 2005, New diabetes drug, FDA Consum, 39, 3
- 2013, Kidney Disease: Improving Global Outcomes. Definition and classification of CKD, KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl, 3, 19
- Østergaard, 2015, Effects of liraglutide as add-on to insulin on counter-regulatory hormone responses, gastric emptying and glycaemic recovery during hypoglycaemia (Abstract), Diabetologia, 58, A963
Cited by
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
“Addition of liraglutide, either in a treat-to-target trial design or on top of capped insulin regimens, resulted in weight loss and reduction in insulin dose, but only modest reduction in A1c, and increased rates of gastrointestinal adverse events (AEs), ketoacidosis, and symptomatic hypoglycemia (Ahrén et al., 2016;…”
Background9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s009 · Cited by 851
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s009 · Cited by 728
Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0043 · Cited by 699
“4% [2–4 mmol/mol]), decreases in weight ( 5 kg), and reductions in insulin doses (257,258).”
Self-citation9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s009 · Cited by 662
Glucagon-like peptide 1 in health and disease
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Self-citationHolt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05568-3 · Cited by 378
Self-citationThe anti-inflammatory and immunological properties of GLP-1 Receptor Agonists
Bendotti, G., Montefusco, L., Lunati, M. E., Usuelli, V., Pastore, I., Lazzaroni, E., Assi, E., Seelam, A. J., El Essawy, B., Jang, J., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106320 · Cited by 406
Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials
Rosenstock, J., Marquard, J., Laffel, L. M., Neubacher, D., Kaspers, S., Cherney, D. Z., Zinman, B., Skyler, J. S., George, J., Soleymanlou, N., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1749 · Cited by 363
Dandona, P., Mathieu, C., Phillip, M., Hansen, L., Griffen, S. C., Tschöpe, D., Thorén, F., Xu, J., Langkilde, A. M., Proietto, J., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30308-x · Cited by 293
Self-citation9. pharmacologic approaches to glycemic treatment: standards of care in diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s009 · Cited by 263
Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era
Akil, A. A.-S., Yassin, E., Al-Maraghi, A., Aliyev, E., Al-Malki, K., & Fakhro, K. A. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02778-6 · Cited by 168
Obesity in people living with type 1 diabetes
Van der Schueren, B., Ellis, D., Faradji, R. N., Al-Ozairi, E., Rosen, J., & Mathieu, C. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00246-1 · Cited by 185
Self-citationCurrent and future therapies for type 1 diabetes
von Scholten, B. J., Kreiner, F. F., Gough, S. C. L., & von Herrath, M. (2021) · Diabetologia · doi:10.1007/s00125-021-05398-3 · Cited by 173
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.04.023 · Cited by 154
Double diabetes—when type 1 diabetes meets type 2 diabetes: definition, pathogenesis and recognition
Bielka, W., Przezak, A., Molęda, P., Pius‐Sadowska, E., & Machaliński, B. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02145-x · Cited by 172
“The ADJUNCT trials showed that liraglutide administration reduced HbA1c, daily dose of insulin and body weight in type 1 diabetic patients, but increased the risk of hypoglycaemia and ketosis [134, 135].”
BackgroundMozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · Obesity · doi:10.1002/oby.24336 · Cited by 143
“Discontinuation or reduction of sulfonylureas and insulin should occur with careful monitoring by the primary care or provider, as appropriate, for individuals with type 2 diabetes interested in a ketogenic diet [293, 294].”
Hu, W., Song, R., Cheng, R., Liu, C., Guo, R., Tang, W., Zhang, J., Zhao, Q., Li, X., & Liu, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.927859 · Cited by 127
SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study
Anson, M., Zhao, S. S., Austin, P., Ibarburu, G. H., Malik, R. A., & Alam, U. (2023) · Diabetologia · doi:10.1007/s00125-023-05975-8 · Cited by 103
New advances in type 1 diabetes
Subramanian, S., Khan, F., & Hirsch, I. B. (2024) · BMJ · doi:10.1136/bmj-2023-075681 · Cited by 88
Self-citationBajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s008 · Cited by 162
Obesity in Patients with Type 1 Diabetes: Links, Risks and Management Challenges
Vilarrasa, N., San Jose, P., Rubio, M. Á., & Lecube, A. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s223618 · Cited by 88
Edwards, K., Li, X., & Lingvay, I. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac618 · Cited by 92
Ghanim, H., Batra, M., Green, K., Abuaysheh, S., Hejna, J., Makdissi, A., Borowski, R., Kuhadiya, N. D., Chaudhuri, A., & Dandona, P. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14090 · Cited by 86
Insulin Resistance in Type 1 Diabetes: Pathophysiological, Clinical, and Therapeutic Relevance
Apostolopoulou, M., Lambadiari, V., Roden, M., & Dimitriadis, G. D. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnae032 · Cited by 90
Efficacy of Semaglutide in Overweight and Obese Patients with Type 1 Diabetes
Garg, S. K., Kaur, G., Haider, Z., Rodriquez, E., Beatson, C., & Snell-Bergeon, J. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0490 · Cited by 78
Dejgaard, T. F., Schmidt, S., Frandsen, C. S., Vistisen, D., Madsbad, S., Andersen, H. U., & Nørgaard, K. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13911 · Cited by 72
“2020;22:492–500.wileyonlinelibrary.com/journal/dom type 1 diabetes in the industrialized part of the world are overweight, and interventions to prevent weight gain are strongly warranted.1,2 Compared with multiple daily injections (MDI) subcutaneous insulin infusion (CSII) therapy improves glycaemic control and reduce…”
BackgroundMethodResultInfluentialMathieu, C., Rudofsky, G., Phillip, M., Araki, E., Lind, M., Arya, N., Thorén, F., Scheerer, M. F., Iqbal, N., & Dandona, P. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14060 · Cited by 71
Self-citationJohansen, N. J., Dejgaard, T. F., Lund, A., Schlüntz, C., Frandsen, C. S., Forman, J. L., Wewer Albrechtsen, N. J., Holst, J. J., Pedersen-Bjergaard, U., Madsbad, S., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30030-9 · Cited by 70
How glucagon-like peptide 1 receptor agonists work
Andreasen, C. R., Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Endocrine Connections · doi:10.1530/ec-21-0130 · Cited by 71
Park, J., Ntelis, S., Yunasan, E., Downton, K. D., Yip, T. C.-F., Munir, K. M., & Haq, N. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad471 · Cited by 69
Prevention of Cardiovascular Disease in Type 1 Diabetes
Manrique‐Acevedo, C., Hirsch, I. B., & Eckel, R. H. (2024) · New England Journal of Medicine · doi:10.1056/nejmra2311526 · Cited by 79
Self-citationPasqua, M.-R., Tsoukas, M. A., Kobayati, A., Aboznadah, W., Jafar, A., & Haidar, A. (2025) · Nature Medicine · doi:10.1038/s41591-024-03463-z · Cited by 68
“Shorter-acting GLP1-RAs have been studied previously in T1D, in particular liraglutide 23,24 .”
Semaglutide in Adults with Type 1 Diabetes and Obesity
Shah, V. N., Akturk, H. K., Kruger, D., Ahmann, A., Bhargava, A., Bakoyannis, G., Pyle, L., & Snell-Bergeon, J. K. (2025) · NEJM Evidence · doi:10.1056/evidoa2500173 · Cited by 62
Sachinidis, A., Nikolic, D., Stoian, A. P., Papanas, N., Tarar, O., Rizvi, A. A., & Rizzo, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154343 · Cited by 58
Dyńka, D., Kowalcze, K., Ambrożkiewicz, F., & Paziewska, A. (2023) · Nutrients · doi:10.3390/nu15030500 · Cited by 58
Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus
Guyton, J., Jeon, M., & Brooks, A. (2019) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxz179 · Cited by 55
Preventing diabetes complications
Templer, S., Abdo, S., & Wong, T. (2024) · Internal Medicine Journal · doi:10.1111/imj.16455 · Cited by 59
Patoulias, D., Doumas, M. N., Kotsis, V., Stavropoulos, K., Imprialos, K. P., Zografou, I., Petidis, K., Bakatselos, S., & Karagiannis, A. I. (2020) · Current Diabetes Reviews · doi:10.2174/1573399815666190614141918 · Cited by 53
Dejgaard, T. F., von Scholten, B. J., Christiansen, E., Kreiner, F. F., Bardtrum, L., von Herrath, M., Mathieu, C., Madsbad, S., & ADJUNCT ONE and ADJUNCT TWO Investigators (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14532 · Cited by 48
“In conclusion, the current post hoc analysis further clarifies the place for GLP-1 RAs as adjuncts to insulin in the management of type 1 diabetes by showing that the efficacy and safety of liraglutide do not differ across clinically relevant subgroups of participants in ADJUNCT ONE and ADJUNCT TWO.”
BackgroundMethodResultInfluentialSelf-citationMaffei, P., Bettini, S., Busetto, L., & Dassie, F. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s240903 · Cited by 49
“83,84 In an RCT that enrolled 26 patients for 12 weeks, it was investigated whether dapagliflozin addition to an already established regimen of insulin and liraglutide results in a significant improvement in glycemia and body weight.”
BackgroundOptimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes
Evans, M., Hicks, D., Patel, D., Patel, V., McEwan, P. C., & Dashora, U. K. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00728-6 · Cited by 48
Pozzilli, P., Bosi, E., Cirkel, D., Harris, J., Leech, N., Tinahones, F. J., Vantyghem, M.-C., Vlasakakis, G., Ziegler, A.-G., & Janmohamed, S. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa149 · Cited by 45
“Two randomized, placebo-controlled, double-blind studies, which were not included in the meta-analysis, assessed liraglutide in patients with type 1 diabetes (10; 11).”
BackgroundThe role of GLP-1 receptor agonists in managing type 2 diabetes
Nachawi, N., Rao, P. P., & Makin, V. (2022) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.89a.21110 · Cited by 45
“…ONE trial (Effi cacy and Safety of Lira-glutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes), 55 the ADJUNCT TWO trial, 56 and a large meta-analysis 57 found reductions in hemoglobin A1c, body weight, and total daily dose of insulin, but also highlighted an increase in…”
BackgroundReducing Type 1 Diabetes Mortality: Role for Adjunctive Therapies?
Snaith, J. R., Holmes-Walker, D. J., & Greenfield, J. R. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2019.11.007 · Cited by 45
Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus
Tan, X., Pan, X., Wu, X., Zheng, S., Chen, Y., Liu, D., & Zhang, X. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.975880 · Cited by 44
Rydén, A. K., Perdue, N., Pagni, P. P., Gibson, C. B., Ratliff, S. S., Kirk, R. K., Friesen, T. J., Haase, C., Coppieters, K. T., von Herrath, M. G., et al. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.07.006 · Cited by 45
Herold, K. C., Reynolds, J., Dziura, J., Baidal, D., Gaglia, J., Gitelman, S. E., Gottlieb, P. A., Marks, J., Philipson, L. H., Pop‐Busui, R., et al. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14121 · Cited by 41
“weight and insulin requirements, but with higher rates of hypoglycaemia and ketosis.(13) The differences between the adverse events in the present study and the ADJUNCT trials may reflect our”
BackgroundKlein, K. R., Freeman, J. L. R., Dunn, I. M., Dvergsten, C., Kirkman, M. S., Buse, J. B., Valcarce, C., Buse, J. B., Klein, K. R., Kirkman, M. S., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2684 · Cited by 44
“CGM average glucose reading (mg/dL), mean (SD) 159 (14) 155 (15) 158 (26) 167 (30)”
Self-citationLu, J., Tang, L., Meng, H., Zhao, J., & Liang, Y. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3169 · Cited by 41
“More importantly, this increased reduction in HbA1c was achieved without any increase in hypoglycaemia or severe hypoglycaemia, a risk observed in other drug classes when used as adjunct therapy to insulin.(24) The results suggested that the combination of SGLT inhibitors with basal insulin emerges as an ideal treatme…”
BackgroundFrandsen, C. S., Dejgaard, T. F., Andersen, H. U., Holst, J. J., Hartmann, B., Thorsteinsson, B., & Madsbad, S. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12830 · Cited by 40
The future of type 1 diabetes therapy
Ziegler, A.-G., Cengiz, E., & Kay, T. W. H. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01438-2 · Cited by 42
Shao, S., Zhang, X., Xu, Q., Pan, R., & Chen, Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108270 · Cited by 46
Glycemic Management in Adults With Type 1 Diabetes
McGibbon, A., Adams, L., Ingersoll, K. S., Kader, T., & Tugwell, B. D. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.012 · Cited by 58
Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Placebo-Controlled Clinical Trial
SNAITH, J. R., Frampton, R., Samocha‐Bonet, D., & Greenfield, J. R. (2025) · Diabetes Care · doi:10.2337/dc25-2379 · Cited by 51
Leahy, J. (. L., Aleppo, G., Fonseca, V. A., Garg, S. K., Hirsch, I. B., McCall, A. L., McGill, J. B., & Polonsky, W. H. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00222 · Cited by 34
“However, in both ADJUNCT ONE and TWO, liraglutide’s effects on glycemic control were significantly better in C-peptide–positive patients compared with patients with undetectable C-peptide, a finding deserving additional consideration [78, 79].”
Self-citationArredouani, A. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108824 · Cited by 36
Shah, V. N., Peters, A. L., Umpierrez, G. E., Sherr, J. L., Akturk, H. K., Aleppo, G., Bally, L., Cengiz, E., Cinar, A., Dungan, K., et al. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241291512 · Cited by 36
“12,13 This is most likely due to depression of glucagon levels after meals and reduced postprandial glucose excursions.”
InfluentialKobayati, A., Haidar, A., & Tsoukas, M. A. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14637 · Cited by 39
“Finally, the authors noted significant CGM improvements in the percent time spent between 3.9 and 8.9 mmol/L and at >8.9 mmol/L, without jeopardizing time spent at 3.9 mmol/L.34 Using a double-blind, randomized controlled, four-way parallel design,35 a single-centre trial investigated once-daily liraglutide at the 0.6…”
InfluentialAdjunctive therapy for glucose control in patients with type 1 diabetes
Harris, K., Boland, C. L., Meade, L. T., & Battise, D. M. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s141700 · Cited by 37
“Neither study found significantly higher rates of severe hypoglycemia with liraglutide.(49,50) Of note, each study included 6%–7% of patients with a history of severe hypoglycemia or hypoglycemia unawareness.”
BackgroundMethodInfluentialKetogenic diets in the management of type 1 diabetes: Safe or safety concern?
Buehler, L. A., Noe, D. R., Knapp, S., Isaacs, D. M., & Pantalone, K. M. (2021) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.88a.20121 · Cited by 33
Sridhar, V. S., Limonte, C. P., Groop, P., Heerspink, H. J. L., Pratley, R. E., Rossing, P. R., Skyler, J. S., & Cherney, D. Z. I. (2023) · Diabetologia · doi:10.1007/s00125-023-06015-1 · Cited by 34
“The ADJUNCT ONE and ADJUNCT TWO trials together randomised >2000 adults with type 1 diabetes to once-daily subcutaneous injections of liraglutide compared with placebo in addition to insulin for 26 and 52 weeks, respectively [53, 54].”
MethodPossible Ways to Improve Postprandial Glucose Control in Type 1 Diabetes
Aktürk, H. K., Rewers, A. H., Joseph, H., Schneider, N., & Garg, S. K. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0114 · Cited by 38
Schmidt, S., Frandsen, C. S., Dejgaard, T. F., Vistisen, D., Halldórsson, T., Olsen, S. F., Jensen, J. B., Madsbad, S., Andersen, H. U., & Nørgaard, K. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14567 · Cited by 29
“Stimulated C-peptide, pmol/L 9 (7-18) 9 (6-12)”
Dejgaard, T. F., Frandsen, C. S., Kielgast, U., Størling, J., Overgaard, A. J., Svane, M. S., Olsen, M. H., Thorsteinsson, B., Andersen, H. U., Krarup, T., et al. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15889 · Cited by 29
“31 In another trial, adults with type 1 diabetes and a mean time from diagnosis of approximately 11 weeks were randomized to treatment with an IL-21 antibody, liraglutide, IL-21 antibody + liraglutide or placebo, as an adjunct to insulin therapy.”
Groot, A. S. D., Skowron, G., White, J. R., Boyle, C., Richard, G., SERREZE, D. V., & Martin, W. D. (2019) · Scientific Reports · doi:10.1038/s41598-019-52331-1 · Cited by 30
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100181 · Cited by 28
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J. P., Butsch, W. S., Christensen, S. M., Gianos, E., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2026.100269 · Cited by 41
Delrue, C., & Speeckaert, M. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179351 · Cited by 28
“The most common side effect of liraglutide was again gastrointestinal distress, which was well tolerated [22].”
BackgroundTandon, S., Ayis, S. A., Hopkins, D. L., Harding, S., & Stadler, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14221 · Cited by 32
Microbiota: A potential orchestrator of antidiabetic therapy
Liu, B., Zhang, L., Yang, H., Zheng, H., & Liao, X. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.973624 · Cited by 31
Effect of low dose Semaglutide in people with Type 1 Diabetes and excess weight
Grassi, B. A., Onetto, M. T., Sánchez, C., Tapia, N., & Salas, F. M. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111593 · Cited by 26
Liraglutide acutely suppresses glucagon, lipolysis and ketogenesis in type 1 diabetes
Garg, M., Ghanim, H., Kuhadiya, N. D., Green, K., HEJNA, J. M., Abuaysheh, S., Torre, B., Batra, M., Makdissi, A., Chaudhuri, A., et al. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12944 · Cited by 26
“In the context of the suppression of ketogenesis by liraglutide, it is relevant that the occurrence of DKA in patients with T1DM treated with this drug numerically was more frequent when compared with that in the placebo arm in the large ADJUNCT ONE and ADJUNCT TWO studies.(15,19) This is intriguing and may be related…”
ResultWright, L. A.-C., & Hirsch, I. B. (2019) · Diabetic Medicine · doi:10.1111/dme.13941 · Cited by 29
Self-citationPramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes
Galderisi, A., Sherr, J., VanName, M., Carria, L., Zgorski, M., Tichy, E., Weyman, K., Cengiz, E., Weinzimer, S., & Tamborlane, W. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02265 · Cited by 25
Incretin-based therapies for patients with type 1 diabetes: a meta-analysis
Liu, L., Shao, Z., Xia, Y., Qin, J., Xiao, Y., Zhou, Z., & Mei, Z. (2019) · Endocrine Connections · doi:10.1530/ec-18-0546 · Cited by 26
Effectiveness and Safety of GLP-1 Receptor Agonists in Patients with Type 1 Diabetes
Almohareb, S. N., Alfayez, O. M., Aljuaid, S. S., Alshahrani, W. A., Bakhsh, G. H., Alshammari, M. K., Yami, M. S. A., Alshaya, O. A., Alomran, A. S., Korayem, G. B., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216532 · Cited by 25
“A reduction in insulin dose requirement with GLP-1RA could raise the risk of DKA, which could partially explain the increased hyperglycemia with ketosis events in controlled settings [10,11].”
BackgroundResultInfluentialKim, Y. J., Hwang, S. D., & Lim, S. K. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00553 · Cited by 24
Metabolic Control in Type 1 Diabetes: Is Adjunctive Therapy the Way Forward?
Warnes, H., Helliwell, R., Pearson, S. M., & Ajjan, R. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0496-z · Cited by 27
GLP-1 receptor agonists in type 1 diabetes: a MAG1C bullet?
Nauck, M. A., & Meier, J. J. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30043-7 · Cited by 24
Glucagon-like peptide-1 receptor agonists and type 1 diabetes: a potential game changer?
Resnick, O., Bril, F., & Beauchamp, G. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1520313 · Cited by 25
Johansen, N. J., Dejgaard, T. F., Lund, A., Schlüntz, C., Hartmann, B., Holst, J. J., Vilsbøll, T., Andersen, H. U., & Knop, F. K. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14568 · Cited by 23
Halperin, I. J., Wicklow, B., Amed, S., Chambers, A., Courage, C., Cummings, E., Kirkland, P., MacKay, D., Nakhla, M., Punthakee, Z., et al. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.01.001 · Cited by 22
Villalba, A., Rodríguez-Fernández, S., Perna‐Barrull, D., Ampudia, R.-M., Gómez-Muñoz, L., Pujol‐Autonell, I., Aguilera, E., Coma, M., Cano‐Sarabia, M., Vázquez, F., et al. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00258 · Cited by 24
New Horizons: Emerging Antidiabetic Medications
Mingrone, G., Castagneto‐Gissey, L., & Bornstein, S. R. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac499 · Cited by 22
Al‐Ozairi, E., Irshad, M., Taghadom, E., SOJAN, L. G., Kandari, J. A., Alroudhan, D., & le Roux, C. W. (2023) · Obesity · doi:10.1002/oby.23677 · Cited by 21
“They reported that hypoglycemic events were uniformly distributed throughout the trial [35].”
BackgroundResultDysfunctional β-cell autophagy induces β-cell stress and enhances islet immunogenicity
Austin, M. C., Muralidharan, C., Roy, S., Crowder, J. J., Piganelli, J. D., & Linnemann, A. K. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1504583 · Cited by 19
XU, Y., Malek, N. D., Chang, A. R., Echouffo-Tcheugui, J. B., Selvin, E., Grams, M. E., Fang, M., & Shin, J. (2026) · Nature Medicine · doi:10.1038/s41591-026-04274-0 · Cited by 22
“Two early trials (ADJUNCT ONE and TWO) showed increased risks of symptomatic hypoglycemia and hyperglycemia with ketosis associated with liraglutide 8,9 .”
Ito, A., Horie, I., Miwa, M., Sako, A., Niri, T., Nakashima, Y., Shigeno, R., Haraguchi, A., Natsuda, S., Akazawa, S., et al. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13486 · Cited by 20
Treating obesity in type 1 diabetes mellitus – review of efficacy and safety
Freeby, M., & Lane, K. L. (2023) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000841 · Cited by 23
Overweight and Obesity in Adults with Type 1 Diabetes: A Growing Challenge
Majanović, S. K., Detel, D., Igrec, M., Bergoč, A., Rahelić, V., & Rahelić, D. (2024) · Diabetology · doi:10.3390/diabetology5030018 · Cited by 22
Karakasis, P., Koufakis, T., Patoulias, D., Barkas, F., Klisic, A. N., Mitrović, M., Doumas, M. N., Παπάνας, Ν., & Popovic, D. S. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15979 · Cited by 20
“…the safety and efficacy of lira-glutide as adjunct to insulin treatment in individuals with T1D, namely, the ADJUNCT ONE 27 and the ADJUNCT TWO 28 trials, enrolling 1398 and 835 subjects, respectively, documented that liraglutide compared with placebo resulted in both a significant increase…”
Adjunct therapies in treatment of type 1 diabetes
Goyal, I., Sattar, A., Johnson, M., & Dandona, P. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13078 · Cited by 18
“8 mg) or placebo to an individually capped TDD of insulin.(47) Adjustments in insulin doses within the limits of the insulin cap were allowed following standard medical care.”
MethodWang, W., Gao, Y., Chen, D., Wang, C., Feng, X., & Ran, X. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.05.007 · Cited by 19
Kuhadiya, N. D., Prohaska, B. D., Ghanim, H., & Dandona, P. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13609 · Cited by 19
“caemic control, fewer complications and less hypoglycaemia than those without residual β-cell function.(11,12,15) However, there are no”
BackgroundCengiz, E., Danne, T., Ahmad, T., Ayyavoo, A., Beran, D., Codner, E., Ehtisham, S., Jarosz-Chobot, P., Mungai, L. N. W., Ng, S. M., et al. (2025) · Hormone Research in Paediatrics · doi:10.1159/000543169 · Cited by 17
GLP-1 receptor agonist–induced diabetic ketoacidosis: A case report
Zhang, J., Ma, Y., Zu, Q., Wang, X., & Zhang, Y. (2024) · Medicine · doi:10.1097/md.0000000000039799 · Cited by 18
“Through a literature search, we found that the median BMI of the selected population was 29 kg/m 2 , [16,17] while the BMI of these patients was only 24 kg/m 2 .”
BackgroundMethodInfante, M., Silvestri, F., Padilla, N., Pacifici, F., Pastore, D., Pinheiro, M. M., Caprio, M., Tesauro, M., Fabbri, A., Novelli, G., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041303 · Cited by 20
Metadata
- Authors
- Ahrén, B., Hirsch, I. B., Pieber, T. R., Mathieu, C., Gómez-Peralta, F., Hansen, T. K., Philotheou, A., Birch, S., Christiansen, E., Jensen, T. J., Buse, J. B., & for the ADJUNCT TWO Investigators
- Affiliations
- Lund University, Lund, Sweden
- University of Washington (US)
- Medical University of Graz (AT)
- KU Leuven (BE)
- Hospital General de Segovia, Segovia, Spain
- Aarhus University Hospital (DK)
- University of Cape Town (ZA)
- Novo Nordisk (Denmark) (DK)
- University of North Carolina at Chapel Hill (US)
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-08-04
- Volume
- 39
- Issue
- 10
- Pages
- 1693-1701
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2494601841
- Cited by
- 262
- References
- 36
- Citations by year
- 2026: 38 · 2025: 49 · 2024: 33 · 2023: 25 · 2022: 16 · 2021: 23 · 2020: 29 · 2019: 11 · 2018: 21 · 2017: 10 · 2016: 7
- FWCI
- 16.40
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Scopus (Elsevier) (submittedVersion)
- UNC Libraries
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- liraglutide, type 1 diabetes, GLP-1 receptor agonists, HbA1c, glycemic control, weight loss, insulin dose reduction, hypoglycemia, diabetic ketoacidosis, quality of life
- MeSH terms
- Liraglutide, Adolescent, Adult, Aged, Aged, 80 and over, Diabetes Mellitus, Type 1, Double-Blind Method, Drug Therapy, Combination, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Male, Middle Aged, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.